Molecular pathology and the art of drug design By Dr Keith McCullagh The current explosion of interest in sophisticated genomic technologies, computerised robotics and high throughput screening of diverse molecular libraries appears to have been associated with a reduction in research productivity in recent years, as judged by the rate of new drug approvals. Analysis [...]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!